NKTR - Nektar Therapeutics
Chart Events
Shooting Star
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 23.45 |
| Open | 23.76 |
| Bid | 23.25 x 900 |
| Ask | 23.52 x 900 |
| Day's Range | 23.45 - 24.34 |
| 52 Week Range | 13.63 - 35.31 |
| Volume | 967,361 |
| Avg. Volume | 1,226,332 |
| Market Cap | 4.186B |
| Beta (5Y Monthly) | 1.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.62 |
| Earnings Date | Aug 06, 2020 - Aug 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.21 |
Fair Value
Related Research
- Insider Monkey
Hedge Funds Aren’t Impressed By Nektar Therapeutics (NKTR)
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
- Thomson Reuters StreetEvents
Edited Transcript of NKTR.OQ earnings conference call or presentation 7-May-20 9:00pm GMT
Q1 2020 Nektar Therapeutics Earnings Call
- Zacks
Why Is Nektar (NKTR) Up 12% Since Last Earnings Report?
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- PR Newswire
Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)
Nektar Therapeutics (NASDAQ:NKTR) today announced the presentation of results from the Phase 1b study evaluating multiple ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator, which is being developed as a potential therapeutic for a range of autoimmune disorders, including systemic lupus erythematosus (SLE).
- PR Newswire
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology (EULAR 2020)
Nektar Therapeutics (NASDAQ: NKTR) announced today that it will webcast an analyst and investor conference call on Friday, June 5, 2020 at 11:00 a.m. EDT during EULAR 2020. The event will follow Thursday's virtual poster presentation of the data from a Phase 1b multiple ascending dose study of NKTR-358, a first-in-class investigational regulatory T cell stimulator, in patients with systemic lupus erythematosus.
- GuruFocus.com
7 Stocks Maverick Capital Continues to Buy
Adobe and Avantor make the list Continue reading...
- PR Newswire
Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal
Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of Phase 1 clinical data for its lead immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) in combination with nivolumab, in Cancer Discovery, a journal of the American Association for Cancer Research. Previously published Phase 1 data in Cancer Discovery on BEMPEG, a CD122-preferential IL-2 pathway agonist, demonstrated that when administered as a monotherapy, it was well tolerated and showed clinical activity, including tumor shrinkage and durable disease stabilization, in heavily pretreated patients with solid tumor cancers.1 The manuscript published today presents the safety, immune-activation and efficacy results from a Phase 1 dose-escalation study conducted in 38 patients with immunotherapy-naïve, advanced solid tumors, including melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC).
- Simply Wall St.
Is There An Opportunity With Nektar Therapeutics's (NASDAQ:NKTR) 46% Undervaluation?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Nektar Therapeutics...
- Investing.com
Oppenheimer Sticks to Their Hold Rating for Nektar Therapeutics
Oppenheimer analyst Jay Olson maintained a Hold rating on Nektar Therapeutics (NASDAQ:NKTR) on Sunday, setting a price target of $25, which is approximately 13.53% above the present share price of $22.02.
- Investing.com
H.C. Wainwright Sticks to Their Hold Rating for Nektar Therapeutics
H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Hold rating on Nektar Therapeutics (NASDAQ:NKTR) on Tuesday, setting a price target of $26, which is approximately 25.18% above the present share price of $20.77.
- Zacks
Nektar's (NKTR) Q1 Earnings and Revenues Top Estimates
Nektar (NKTR) reports encouraging first-quarter 2020 results. The company continues to progress with its pipeline candidates.
- Motley Fool
Nektar Therapeutics (NKTR) Q1 2020 Earnings Call Transcript
NKTR earnings call for the period ending March 31, 2020.
- Zacks
Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates
Nektar (NKTR) delivered earnings and revenue surprises of 34.57% and 12.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Nektar Therapeutics Reports First Quarter 2020 Financial Results
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2020.
- PR Newswire
Nektar to Announce Financial Results for the First Quarter 2020 on Thursday, May 7, 2020, After Close of U.S.-Based Financial Markets
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2020 on Thursday, May 7, 2020, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
- American City Business Journals
Clinical trials in the age of COVID: Shelter-in-place, hospital restrictions cause drug study delays
In the span of eight days last month, CytomX Therapeutics Inc. landed a collaboration with Astellas Pharma and captured a $40 million milestone payment from AbbVie Inc. as it preps for a mid-stage cancer clinical trial. “It’s a challenging time for our industry,” said CytomX President and CEO Sean McCarthy.
- Simply Wall St.
Need To Know: Analysts Are Much More Bullish On Nektar Therapeutics (NASDAQ:NKTR) Revenues
Celebrations may be in order for Nektar Therapeutics (NASDAQ:NKTR) shareholders, with the analysts delivering a...
- Insider Monkey
Hedge Funds Are Betting On Nektar Therapeutics (NKTR)
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- Thomson Reuters StreetEvents
Edited Transcript of NKTR earnings conference call or presentation 27-Feb-20 10:00pm GMT
Q4 2019 Nektar Therapeutics Earnings Call
- Simply Wall St.
Nektar Therapeutics Just Reported And Analysts Have Been Cutting Their Estimates
It's been a sad week for Nektar Therapeutics (NASDAQ:NKTR), who've watched their investment drop 12% to US$20.81 in...
- PR Newswire
Nektar Therapeutics to Webcast Presentation at the Cowen and Company 40th Annual Health Care Conference
Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to present at the upcoming Cowen and Company 40th Annual Health Care Conference in Boston on Tuesday, March 3, 2020 at 9:20 a.m. Eastern Time.
- PR Newswire
Nektar Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2019.
- PR Newswire
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2019 on Thursday, February 27, 2020, After Close of U.S.-Based Financial Markets
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2019, on Thursday, February 27, 2020, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.
- GuruFocus.com
Lee Ainslie Buys Crown Holdings, Monster Beverage
Guru's largest buys of the 4th quarter Continue reading...
- Simply Wall St.
Here's What We Think About Nektar Therapeutics's (NASDAQ:NKTR) CEO Pay
Howard Robin became the CEO of Nektar Therapeutics (NASDAQ:NKTR) in 2007. This analysis aims first to contrast CEO...
